Slide 1: ImpediMed ASX announcement: Equity Raising Investor Presentation
ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 4 May 2026 Companies Announcements Office Australian Securities Exchange Equity Raising Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached Equity Raising
Slide 2: Equity Raising Investor Presentation
Equity Raising Investor Presentation ImpediMed Limited (ASX:IPD) 4 May 2026 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited.
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer The following notice and disclaimer apply to this investor presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this P
Slide 4: Important Notice & Disclaimer (cont.)
Important Notice & Disclaimer (cont.) Past performance Past performance metrics and figures (including past share price performance of ImpediMed, as well as pro forma financial information, included in this Presentation are given for illustrative purposes only and should not be relied upon as (and i
Slide 5: Executive Summary
Executive Summary Up to $15.2 million equity raising to pursue capital-light expansion into high-value growth markets and partially prepay debt facility with a reset operating cost base to achieve operating cashflow breakeven in FY28, assuming full exercise of Options FDA-cleared BIS BCRL1: Strong
Slide 6: Transformational Equity Raising to Unlock Growth Opportunities
Transformational Equity Raising to Unlock Growth Opportunities Capitalised to pursue growth initiatives under a capital-light operating model following partial debt prepayment and a reset of the operating cost base Up to $15.2 million $5.0 million Debt Resetting the Pathway to Operating Equity Raisi
Slide 7: Company Overview
Company Overview SOZO® Digital Health Platform – BIS devices that are FDA-cleared for detecting and monitoring fluid and body composition status in high-value indications 3-year average contracted revenue SOZO measures impedance to mild electrical current in a 30-second test across 256 frequencies
Slide 8: Highly Scalable SOZO Platform Assets in Market across High-growth Segments
Highly Scalable SOZO® Platform Assets in Market across 3 High-growth Segments IPD’s proprietary clinical, regulatory and commercial SOZO platform provides significant operating leverage across 3 high growth market segments PROPRIETARY TECHNOLOGY CLINICAL EVIDENCE REGULATORY APPROVALS GUIDELINE R
Slide 9: SOZO Platform: A Durable Foundation for Growth
SOZO® Platform: A Durable Foundation for Growth Accelerating BCRL growth anticipated with >93% National US payer coverage achieved in Q2 FY26 Durable ARR1 growth Growing installed base Over 1.3m patient measurements 14% 19% 3-year 3-year CAGR2 CAGR3 Patient 152 measurements 144 141 (000s) 130 118 1
Slide 10: Growth Runway Unlocked with >93% Payer Coverage Achieved in Q2 FY26
Growth Runway Unlocked with >93% Payer Coverage Achieved in Q2 FY26 Recommended by guidelines and medical societies Long and durable SOZO® growth runway supported by regulatory approvals, clinical adoption, MSAs and payer coverage ~6,000 Eligible SOZO Locations1 • ~300 devices in active sales propos
Slide 11: SOZO: One Platform, Multiple Market Segments, Strong Cross Over
SOZO®: One Platform, Multiple Market Segments, Strong Cross Over SOZO is at the centre of three large and growing structural tailwinds in Cancer Survivorship, Heart Health & Weight Management Demand driven expansion into new adjacencies offers a capital-light Breast Cancer Related Lymphoedema (BCR
Slide 12: Low Friction Growth: Leveraging Existing BCRL Footprint
Low Friction Growth: Leveraging Existing BCRL Footprint into Heart Health and Weight Management Low Friction Growth Opportunity SOZO in 17/20 Top IDNs by Patient Revenue Net Patient Member PC & LM HF SOZO # IDN / Health System HQ Revenue1 Hospitals Clinics2 Clinics3 Devices 1 HCA Healthcare TN $42.
Slide 13: BCRL and Cancer Survivorship
BCRL and Cancer Survivorship Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 12
Slide 14: The Cancer Survivorship Challenge
The Cancer Survivorship Challenge Cancer survivors face compounding risks that current tools don't address >18M 80%+ 1 in 5 1 in 3 cancer patients experience breast cancer patients US cancer survivors at risk for BCRL sarcopenia during develop lymphoedema without growing to 22M by 20351 dependin
Slide 15: Objective, Early Detection and Surveillance of BCRL
Objective, Early Detection and Surveillance of BCRL Current Standard of Care: L-Dex Score Subjective, Time-Consuming or Expensive SOZO® is the only FDA Cleared medical grade BIS technology available to clinicians to objectively detect, measure and inform early intervention and treatment decisions E
Slide 16: Accelerating BCRL Pipeline Opportunities
Accelerating BCRL Pipeline Opportunities Pipeline growth following increased coverage in FY26 and new marketing strategies Sales Pipeline • Increase in payer coverage → key driver in pipeline growth and critical factor for 141% pipeline conversion • ~6-month hospital sales cycle results in lag be
Slide 17: Land-and-Expand Strategy across Leading Health Systems
Land-and-Expand Strategy across Leading Health Systems 250+ device opportunity within existing customer network Major Academic Regional IDN National Cancer Medical Center Health System Network (Eg Cleveland Clinic) (Eg KU Health) (Eg NCCN® Member Centers) ENTRY POINT ENTRY POINT ENTRY POINT Breast S
Slide 18: SOZO: A Financially Viable New Cancer Service Line
SOZO®: A Financially Viable New Cancer Service Line ✓ Clinical evidence ✓ Reimbursement ✓ National Coverage ✓ Financially viable for customers Clinical Benefit Pillars Illustrative ROI Framework Early Detection & Prevention Revenue Streams 92% reduction in chronic lymphoedema progression (PREVENT 9
Slide 19: Next generation SOZO Pro launched in Heart Health
Next generation SOZO® Pro launched in Heart Health Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 18
Slide 20: SOZO Pro for Heart Failure: Addressing a Large Underserved Need
SOZO® Pro for Heart Failure: Addressing a Large Underserved Need Fluid overload (congestion) drives hospitalisation, readmission, and mortality — clinicians lack an objective, real-time measure of fluid status The Burden SOZO Pro Innovates the Problem 6.7M1 $70B1 projected US costs 4.25x ability to
Slide 21: SOZO Pro: Commercial Launch in Heart Health
SOZO® Pro: Commercial Launch in Heart Health Fluid assessment + Body Composition in one 30-second, non-invasive test The Health Opportunity The GLP-1 Body Composition Opportunity SOZO answers this need: 6.7M 29.8% 70-80% CV Indicated US Heart Health Patients HF Readmissions within 30 days of HF pati
Slide 22: SOZO: Non-invasive, Real-time Fluid and Body Composition
SOZO®: Non-invasive, Real-time Fluid and Body Composition CardioMEMS / Pulmonary Artery Pressure (PAP) SOZO Pro (BIS) Weight Scale Monitoring Invasiveness Surgical implant Non-invasive, 30-sec Non-invasive Cost Expensive, narrow eligibility Reimbursed, capital-light No reimbursement Body Composition
Slide 23: SOZO Pro: A Strong Value Ecosystem Proposition
SOZO® Pro: A Strong Value Ecosystem Proposition to Predict and Prevent Impending Heart Failure Events Patient Clinician Hospital Outpatient Clinic Payer / CMS • Prevention of developing / • Early detection and intervention • ~$11K potential cost saved per • Best-in-class clinically driven • Reduced
Slide 24: SOZO Pro: A New, Low Friction Cardiac Service Line
SOZO® Pro: A New, Low Friction Cardiac Service Line Positioning SOZO Pro with HF-Dex® Analysis as a financially viable objective measure that fits within existing clinical workflows SOZO Pro Fit into Existing Clinical Workflow Illustrative ROI Framework Typical facility $ Revenue Streams 3–5 Reimb
Slide 25: Weight Management & Body Composition
Weight Management & Body Composition Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 24
Slide 26: The Rise of GLP-1's and the SOZO Pro Opportunity
The Rise of GLP-1’s and the SOZO® Pro Opportunity Awareness of potential risks of GLP-1’s is growing Multiple key drivers support SOZO Pro adoption and underpinning the rising need for objective Body Composition analysis • Global adoption of GLP-1 pharmacotherapy → 15M US GLP-1 patients (IQVIA/Gabel
Slide 27: End of the BMI Era: Global Guidelines Recommend Body Composition Assessment
End of the BMI Era: Global Guidelines now recommend Personalised Monitoring and Body Composition Assessment Three landmark 2025 guidelines validate the clinical need for objective measurement tools for weight loss management WHO LANCET DE COMMISSION OBESITY SOCIETY + 3 GLP-1 Guideline for Obesity i
Slide 28: Launched in Market with a Focus on Largest Customer Segments
Launched in Market with a Focus on Largest Customer Segments where we have Adjacencies to our BCRL Customer Base Why SOZO® BIS wins in these segments Market Segment Sites of Care Specialty Medicine 4,500 16,500 FDA Cleared · Medical-Grade Accuracy • BIS at 256 frequencies — separates intracellular,
Slide 29: Attractive Customer Clinical Proposition
Attractive Customer Clinical Proposition What Traditional Monitoring with the Scale Missed During 6-Month Weight Loss Patient History 59-year-old female with Class I Obesity and CAD was monitored with SOZO ® BodyComp prior to and during initiation of GLP-1/GIP therapy for weight loss. What the Clini
Slide 30: Clinical and Financial Value Proposition for Weight Loss Clinics
Clinical and Financial Value Proposition for Weight Loss Clinics Illustrative Provider ROI Model Key 3–6 mo 3–5x $23–32K Outpatient Weight Management Clinic Takeaway Payback Period Annual ROI Multiple 3-Year TCV per device Monthly GLP-1 patients >55 Pay for Body Composition (40%) 22 patients/mo Tes
Slide 31: Financial Overview & Debt Prepayment
Financial Overview & Debt Prepayment Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 30
Slide 32: ~16% Operating Cost Reduction – Targeting H2 FY28 Cashflow Breakeven
~16% Operating Cost Reduction – Targeting H2 FY28 Cashflow Breakeven assuming full exercise of Options prior to maturity 25% improvement in H1 FY26 Profit Before Tax (Pro forma)2 $5.0m partial prepayment of debt facility and pro forma net cash position of $5.9 million Capital Debt Pro forma as at $m
Slide 33: FY26 YTD Financial Results Overview
FY26 YTD Financial Results Overview Summarized P/(L) FY26 Financial In thousands Q1 Q2 Q3 YTD AUD Actual Actual Actual Actual • Revenue $11.0m Revenue 3,573 3,943 3,515 11,031 Cost of good sold (425) (515) (366) (1,306) • TCV $14.1m Gross profit 3,148 3,428 3,150 9,726 % 88.1% 86.9% 89.6% 88.2% •
Slide 34: FY26 YTD Cash Flow
FY26 YTD Cash Flow Summarized Cash Flow FY26 Commentary In thousands Q1 Q2 Q3 YTD AUD Actual Actual Actual Actual • Q3 operating cash outflow of $4.5m (vs. Q2 outflow of $2.9m or $4.1m excl. R&D credit). Receipts from customers 3,443 3,785 3,268 10,496 Research & development (62) (125) (48) (235) Pr
Slide 35: Renewed Operating Outlook
Renewed Operating Outlook ImpediMed is well-positioned to deliver revenue growth across existing and new market segments and is targeting operating cashflow breakeven in H2 FY28 assuming full exercise of Options ✓ $5.7 million annualised cost reduction ✓ Pro forma net cash position of $5.9 million a
Slide 36: Transformational Equity Raising
Transformational Equity Raising Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 35
Slide 37: Equity Raising
Equity Raising Equity raising of up to $15.2 million via a $13.2 million Placement and up to $2.0 million SPP • Firm commitments received for an institutional placement of new fully paid ordinary shares in ImpediMed (“New Shares”) to raise up to $13.2 million comprising: o ~$3.0 million via the issu
Slide 38: Use of Funds and Timetable
Use of Funds and Timetable Sources (A$m)1 Timetable Placement $13.2 Record Date for SPP Friday, 1 May 2026 Trading resumes and Announcement of Equity Raising Monday, 4 May 2026 SPP $2.0 Settlement of Tranche 1 Placement Shares Thursday, 7 May 2026 Total Sources $15.2 Allotment of Tranche 1 Shares Fr
Slide 39: ImpediMed Board and Management
ImpediMed Board and Management Executive Directors Non-Executive Directors Erik Anderson McGregor Grant Christine Emmanuel- Janelle Delaney Fiona Bones Andrew Grant CEO and Managing CF&OO / Executive Donnelly Non-Executive Director Non-Executive Director Non-Executive Director Director Director Non-
Slide 40: Appendix
Appendix Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 39
Slide 41: Key Risks
Key Risks COMPANY-SPECIFIC RISKS SWK Growth Capital Facility Under the Facility, the liquidity covenant and performance covenant are scheduled to be tested for the period ending 31 March 2026 in mid April. However, the Company and the lender SWK Funding LLC agreed that if the Company raises at least
Slide 42: Key Risks (cont.)
Key Risks (cont.) Dividend Policy The Company has never paid a dividend and does not intend to pay dividends in the foreseeable future, which means that holders of Shares may not receive any return on their investment from dividends in the short to medium term. Pricing and reimbursement The commerci
Slide 43: Key Risks (cont.)
Key Risks (cont.) Changes in laws and healthcare policy The Company's business and the business of the third parties with which it operates are subject to the laws and regulations in a number of jurisdictions. Unforeseen changes in laws and government policy in the US, the EU, Australia and elsewher
Slide 44: Key Risks (cont.)
Key Risks (cont.) Brand and reputation The reputation and brand of the Company and its products are important in attracting hospitals, medical clinics, large companies and healthcare professionals to use the Company products. Any reputation damage or negative publicity around the Company or its prod
Slide 45: Key Risks (cont.)
Key Risks (cont.) General economic factors Material adverse changes in the general domestic and international economic climate may have an adverse effect on the Company's performance. These factors may include fluctuations in inflation, interest rates, rate of economic growth, taxation laws (and the
Slide 46: International Offer Restrictions
International Offer Restrictions This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any c
Slide 47: ImpediMed
impedimed’